Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02883660 · ClinicalTrials.gov registry record
Genecept Assay and Adverse Effects of Antidepressants
A clinical trial, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- 74
- Enrollment target
NCT02883660 is a clinical trial that has completed, run by Thomas Jefferson University. The registered enrollment target is 74 participants.
The verdict
NCT02883660 has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- 74 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether patients who have been prescribed antidepressant medications and have experienced significant adverse effects are more likely to be poor metabolizers on the CYP450 (CYP2B6, CYP2D6, CYP2C19, CYP3A4/5+) drug metabolizing enzymes and/or homozygous for the short allele of the serotonin transporter (SLC6A4) compared to patients who took an antidepressant medication and did not experience significant adverse effects but also had minimal or no response to the medication. The target medications being studied include escitalopram, citalopram, paroxetine, fluvoxamine, venlafaxine, duloxetine, bupropion, vortioxetine, vilazodone, and levomilnacipran only.
Interventions
- GENETIC Genocept Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2013-02 |
| Est. Completion | 2018-02-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02883660
The ClinicalTrials.gov registry entry for NCT02883660 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Genocept Assay is the first listed.
NCT02883660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02883660 about?
NCT02883660 is a clinical study titled "Genecept Assay and Adverse Effects of Antidepressants". The purpose of this study is to determine whether patients who have been prescribed antidepressant medications and have experienced significant adverse effects are more likely to be poor metabolizers on the CYP450 (CYP2B6, CYP2D6, CYP2C19, CYP3A4/5+) drug metabolizing enzymes and/or homozygous for t...
What is the current status of trial NCT02883660?
This trial is currently completed. The enrollment target is 74 participants. The study started on 2013-02. Estimated completion is 2018-02-01.
What interventions are being tested in trial NCT02883660?
The interventions under investigation include: Genocept Assay (GENETIC).
Who is sponsoring clinical trial NCT02883660?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.